Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported TissueTech\'s research with more than 25 continuous years of research grants. Since inception, 150,000 human implants have been conducted using the Company\'s patented CryoTek⢠process and 300 peer-reviewed scientific publications have been produced supporting the technology platform.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/22/13 | $10,000,000 | Growth |
Ballast Point Ventures River Cities Capital Funds | undisclosed |
| 06/26/19 | $82,000,000 | Series C |
Ballast Point Ventures EW Healthcare Partners  | undisclosed |
